Cargando…

Perceptions of and barriers to ethical promotion of pharmaceuticals in Pakistan: perspectives of medical representatives and doctors

BACKGROUND: In Pakistan, drug promotion practices, ethical or unethical, have rarely been in the spotlight. We aimed to assess the perception and barriers of medical representatives (MRs) and doctors (MDs) regarding ethical promotion of pharmaceuticals in Pakistan. METHODS: A cross sectional survey...

Descripción completa

Detalles Bibliográficos
Autores principales: Gul, Rehan, Saeed, Hamid, Saleem, Zikria, Rasool, Fawad, Hashmi, Furqan Kurshid, Islam, Muhammad, Imran, Imran, Raza, Syed Atif, Danish, Zeeshan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7783997/
https://www.ncbi.nlm.nih.gov/pubmed/33397339
http://dx.doi.org/10.1186/s12910-020-00569-0
_version_ 1783632214611722240
author Gul, Rehan
Saeed, Hamid
Saleem, Zikria
Rasool, Fawad
Hashmi, Furqan Kurshid
Islam, Muhammad
Imran, Imran
Raza, Syed Atif
Danish, Zeeshan
author_facet Gul, Rehan
Saeed, Hamid
Saleem, Zikria
Rasool, Fawad
Hashmi, Furqan Kurshid
Islam, Muhammad
Imran, Imran
Raza, Syed Atif
Danish, Zeeshan
author_sort Gul, Rehan
collection PubMed
description BACKGROUND: In Pakistan, drug promotion practices, ethical or unethical, have rarely been in the spotlight. We aimed to assess the perception and barriers of medical representatives (MRs) and doctors (MDs) regarding ethical promotion of pharmaceuticals in Pakistan. METHODS: A cross sectional survey was conducted in seven major cities of Pakistan for 6-months period. Self-administered questionnaire was used for data collection. Logistic regression and five-point Likert scale scoring was used to estimate the perceptions and barriers. RESULTS: Compared to national companies (NCs), the medical representatives (MRs) of multinational companies (MNCs) strongly believed that their companies follow World Health Organization (WHO) (OR; 5.31, p = 0.0005), International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) (OR; 6.45, p = 0.0005) and national codes of ethics (OR; 5.84, p = 0.0005). MNCs trained their MRs (OR; 6.68, p = 0.0005), provide accurate and valid scientific data (OR; 4.01, p = 0.007) with adequate system of accountability and controls on product samples (OR; 1.96, p = 0.047), while, NCs sponsor social or entertainment activities, seminars and conferences, and all sort of facilitation in form of gifts of their choice and clinic renovation for medical doctors (MDs). MDs perceptions were similar to MRs mentioned above, yet strongly agreed that companies offer cash payments or equivalents to MDs. The MRs of NCs/MNCs and MDs agreed/strongly agreed that no external accountability, profiteering, pressure on sale targets, job insecurity, condoning unethical promotion by high-ups’ and business promotion by junior MDs were the predominant barriers. CONCLUSION: In conclusion, MRs of MNCs and MDs believed that MNCs follow certain codes of ethics in the promotion of pharmaceuticals, while NCs tend to be more profit oriented and even condone unethical promotion. All stakeholders, MRs, MDs and companies, might pose certain barriers, intentionally or unintentionally, in ethical promotion.
format Online
Article
Text
id pubmed-7783997
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-77839972021-01-14 Perceptions of and barriers to ethical promotion of pharmaceuticals in Pakistan: perspectives of medical representatives and doctors Gul, Rehan Saeed, Hamid Saleem, Zikria Rasool, Fawad Hashmi, Furqan Kurshid Islam, Muhammad Imran, Imran Raza, Syed Atif Danish, Zeeshan BMC Med Ethics Research Article BACKGROUND: In Pakistan, drug promotion practices, ethical or unethical, have rarely been in the spotlight. We aimed to assess the perception and barriers of medical representatives (MRs) and doctors (MDs) regarding ethical promotion of pharmaceuticals in Pakistan. METHODS: A cross sectional survey was conducted in seven major cities of Pakistan for 6-months period. Self-administered questionnaire was used for data collection. Logistic regression and five-point Likert scale scoring was used to estimate the perceptions and barriers. RESULTS: Compared to national companies (NCs), the medical representatives (MRs) of multinational companies (MNCs) strongly believed that their companies follow World Health Organization (WHO) (OR; 5.31, p = 0.0005), International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) (OR; 6.45, p = 0.0005) and national codes of ethics (OR; 5.84, p = 0.0005). MNCs trained their MRs (OR; 6.68, p = 0.0005), provide accurate and valid scientific data (OR; 4.01, p = 0.007) with adequate system of accountability and controls on product samples (OR; 1.96, p = 0.047), while, NCs sponsor social or entertainment activities, seminars and conferences, and all sort of facilitation in form of gifts of their choice and clinic renovation for medical doctors (MDs). MDs perceptions were similar to MRs mentioned above, yet strongly agreed that companies offer cash payments or equivalents to MDs. The MRs of NCs/MNCs and MDs agreed/strongly agreed that no external accountability, profiteering, pressure on sale targets, job insecurity, condoning unethical promotion by high-ups’ and business promotion by junior MDs were the predominant barriers. CONCLUSION: In conclusion, MRs of MNCs and MDs believed that MNCs follow certain codes of ethics in the promotion of pharmaceuticals, while NCs tend to be more profit oriented and even condone unethical promotion. All stakeholders, MRs, MDs and companies, might pose certain barriers, intentionally or unintentionally, in ethical promotion. BioMed Central 2021-01-04 /pmc/articles/PMC7783997/ /pubmed/33397339 http://dx.doi.org/10.1186/s12910-020-00569-0 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Gul, Rehan
Saeed, Hamid
Saleem, Zikria
Rasool, Fawad
Hashmi, Furqan Kurshid
Islam, Muhammad
Imran, Imran
Raza, Syed Atif
Danish, Zeeshan
Perceptions of and barriers to ethical promotion of pharmaceuticals in Pakistan: perspectives of medical representatives and doctors
title Perceptions of and barriers to ethical promotion of pharmaceuticals in Pakistan: perspectives of medical representatives and doctors
title_full Perceptions of and barriers to ethical promotion of pharmaceuticals in Pakistan: perspectives of medical representatives and doctors
title_fullStr Perceptions of and barriers to ethical promotion of pharmaceuticals in Pakistan: perspectives of medical representatives and doctors
title_full_unstemmed Perceptions of and barriers to ethical promotion of pharmaceuticals in Pakistan: perspectives of medical representatives and doctors
title_short Perceptions of and barriers to ethical promotion of pharmaceuticals in Pakistan: perspectives of medical representatives and doctors
title_sort perceptions of and barriers to ethical promotion of pharmaceuticals in pakistan: perspectives of medical representatives and doctors
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7783997/
https://www.ncbi.nlm.nih.gov/pubmed/33397339
http://dx.doi.org/10.1186/s12910-020-00569-0
work_keys_str_mv AT gulrehan perceptionsofandbarrierstoethicalpromotionofpharmaceuticalsinpakistanperspectivesofmedicalrepresentativesanddoctors
AT saeedhamid perceptionsofandbarrierstoethicalpromotionofpharmaceuticalsinpakistanperspectivesofmedicalrepresentativesanddoctors
AT saleemzikria perceptionsofandbarrierstoethicalpromotionofpharmaceuticalsinpakistanperspectivesofmedicalrepresentativesanddoctors
AT rasoolfawad perceptionsofandbarrierstoethicalpromotionofpharmaceuticalsinpakistanperspectivesofmedicalrepresentativesanddoctors
AT hashmifurqankurshid perceptionsofandbarrierstoethicalpromotionofpharmaceuticalsinpakistanperspectivesofmedicalrepresentativesanddoctors
AT islammuhammad perceptionsofandbarrierstoethicalpromotionofpharmaceuticalsinpakistanperspectivesofmedicalrepresentativesanddoctors
AT imranimran perceptionsofandbarrierstoethicalpromotionofpharmaceuticalsinpakistanperspectivesofmedicalrepresentativesanddoctors
AT razasyedatif perceptionsofandbarrierstoethicalpromotionofpharmaceuticalsinpakistanperspectivesofmedicalrepresentativesanddoctors
AT danishzeeshan perceptionsofandbarrierstoethicalpromotionofpharmaceuticalsinpakistanperspectivesofmedicalrepresentativesanddoctors